SYK - Stryker Corporation
| Previous Close | 174.30 |
| Open | 174.18 |
| Bid | 173.46 x 800 |
| Ask | 173.56 x 900 |
| Day's Range | 172.89 - 174.24 |
| 52 Week Range | 137.70 - 179.84 |
| Volume | 88,677 |
| Avg. Volume | 1,404,792 |
| Market Cap | 64.753B |
| Beta | 0.47 |
| PE Ratio (TTM) | 64.85 |
| EPS (TTM) | 2.67 |
| Earnings Date | Jul 24, 2018 |
| Forward Dividend & Yield | 1.88 (1.08%) |
| Ex-Dividend Date | 2018-06-28 |
| 1y Target Est | 181.91 |
- Zacks•3 hours ago
Here's Why You Should Invest in DaVIta (DVA) Stock Right Now
Strong fundamentals and solid international presence make DaVita (DVA) a lucrative pick.
- ACCESSWIRE•4 hours ago
Free Pre-Market Technical Recap on Nevro and Three Additional Medical Equipment Stocks
On Friday, July 13, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Six out of nine sectors ended Friday's trading session in bullish territories. Taking into consideration last Friday's market sentiment, WallStEquities.com assessed the following Medical Appliances & Equipment equities this morning: Nevro Corp. (NYSE: NVRO), NovoCure Ltd (NASDAQ: NVCR), NuVasive Inc. (NASDAQ: NUVA), and Stryker Corp. (NYSE: SYK).
- Zacks•3 days ago
QIAGEN Test-Menu Expansion on Track, Low HPV Sales a Woe
QIAGEN's (QGEN) HPV sales in the United States remain tepid. Weak APAC sales are due to bleak applied testing business.
- Zacks•4 days ago
Can Medical Devices Strength Drive Abbott (ABT) Q2 Earnings?
Abbott (ABT) poised to gain on continued growth in Medical Devices business in Q2.
- Zacks•5 days ago
Can Abbott (ABT) Rise on Robust Overall Growth in Q2 Earnings?
Abbott (ABT) gains traction from a steady healthy growth trajectory seen in core Diabetes Care business.
- Zacks•5 days ago
BD Buys TVA Medical, To Provide Minimally Invasive Procedure
The acquisition of TVA Medical will enable Becton, Dickinson (BDX) to treat patients with chronic kidney disease through minimally invasive procedures.
- Zacks•6 days ago
Why You Should Add Boston Scientific (BSX) to Your Portfolio
Boston Scientific's (BSX) agreement for Cryterion Medical buyout in the field of atrial fibrillation buoys investor optimism on the stock.
- MarketWatch•6 days ago
Stryker names Timothy Scannell president and COO effective Aug. 1
MARKET PULSE Medical-tech company Stryker Corp. (syk) said Tuesday it has named Timothy Scannell president and chief operating officer, effective Aug. 1. The company is making the change as David Floyd, group president, orthopaedics, is retiring on June 30, 2019.
- GlobeNewswire•6 days ago
Stryker announces organizational changes
July 10, 2018 - Stryker Corporation (SYK) announced today that David K. Floyd, Group President, Orthopaedics has notified the Company of his intent to retire on June 30, 2019. Until this date, Mr. Floyd will serve as Group President and Advisor to the CEO and will assist with transitioning his responsibilities to our newly appointed leaders while also contributing to strategic growth projects. Mr. Floyd joined Stryker in 2012 after 25 successful years in the medical technology industry. David has served as a key member of Stryker`s leadership team and enjoyed terrific success leading our Orthopaedics group.
- Zacks•7 days ago
Medtronic (MDT) Rides on Innovation, Rising Costs a Woe
Medtronic (MDT) continues to meaningfully accelerate all its three fundamental growth strategies, namely therapy innovation, globalization and economic value.
- Zacks•7 days ago
Intuitive Surgical's FDA Approval for SureForm to Aid Surgery
Intuitive Surgical's (ISRG) SureForm 60 stapler receives FDA approval; strengthens its profile for minimally invasive surgical solutions.
- Zacks•7 days ago
Will Core Segmental Growth Aid Stryker (SYK) in Q2 Earnings?
Stryker's (SYK) strong segmental performance and acquisition-driven strategy are likely to drive Q2 earnings.
- Zacks•10 days ago
Boston Scientific to Buy Cryterion Medical to Widen EP Suite
Boston Scientific (BSX) forges ahead with initiatives to strengthen its hold in the high-potential EP market.
- Zacks•11 days ago
Insulet Omnipod Insulin Pump Finds Favor in British Columbia
Insulet's (PODD) Omnipod has huge market potential in Canada as it is the only tubeless insulin pump sold in the region.
- Zacks•12 days ago
Here's Why You Should Invest in Masimo (MASI) Right Now
Masimo's (MASI) raised guidance for 2018 and strong fundamentals make it a lucrative pick.
- Zacks•13 days ago
Insulet Starts European Direct Operation, Braces Global Base
Insulet's (PODD) goal to begin direct commercial operation in Europe is a year-long endeavor.
- Zacks•13 days ago
Integer Holdings Offloads AS&O, Focuses on Cardiac Units
Integer Holdings (ITGR) divests core AS&O unit to MedPlast, LLC for $600 million; aims to focus on cardiac business.
- Zacks•13 days ago
Insulet Banks on Omnipod's Growing Market Reach, Runs Risks
We are upbeat about the solid uptake of Insulet's (PODD) Omnipod System in the United States and other geographies.
- Zacks•14 days ago
Here's Why You Should Hold Wright Medical (WMGI) Stock Now
Here we take a quick look at the major factors that have been plaguing Wright Medical and discuss the prospects that ensure near-term recovery.
- Zacks•14 days ago
Stryker or Baxter: Which is a Better Pick for Your Portfolio?
Stryker (SYK) and Baxter's (BAX) strong expected growth rates and rising share price make them close contenders in the MedTech industry.
- Zacks•17 days ago
McKesson (MCK) Issues Strong Preliminary Results for Q1
McKesson Corporation (MCK) declares solid preliminary results for Q1, courtesy of deals, divestitures and acquisitions.
- Zacks•18 days ago
Stryker (SYK) to Acquire SafeAir, Reduce Surgical Smoke
The acquisition of SafeAir likely to boost Stryker's (SYK) core MedSurg and Neurotechnology segments.
- Zacks•19 days ago
Align Scripts New Success in EMEA, Lifts Global Progress
Align (ALGN) attains a significant milestone with accelerated adoption of Invisalign clear aligner therapy.
- Zacks•19 days ago
Here's Why You Should Hold on to Becton, Dickinson Stock Now
Becton, Dickinson (BDX) gains from strong fundamentals. Recent product recall issues raise concern.
- Zacks•19 days ago
Integra LifeSciences Global Prospects Solid, Competition Rife
Integra LifeSciences (IART) continues to expand overseas.
